Spotlight On... Valeant's meltdown claims another top exec, this time at shareholder Sequoia; Gilead CEO vows to fight Merck's hep C patent win; NJ judge consolidates compulsive gambling claims against Abilify; and more...

Sequoia Fund chief Robert Goldfarb bowed out of his post Wednesday after his big bet on Valeant Pharmaceuticals ($VRX) turned up sour. One of the embattled drugmaker's biggest shareholders, Sequoia at one point had 30% of its capital tied up in Valeant, MarketWatch reports. Report

@FiercePharma: Roslin turns to business with new animal health venture. FierceAnimalHealth article | Follow @FiercePharma

@CarlyHFierce: Lilly's new psoriasis med Taltz sets up head-to-head with Novartis' Cosentyx. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Gilead Sciences ($GILD) CEO John Milligan confirmed that his company will appeal a patent decision that could deliver royalties to Merck & Co. ($MRK) on Gilead's blockbuster hep C meds Sovaldi and Harvoni. Report

> A New Jersey judge consolidated pretrial work on suits alleging that the Bristol-Myers Squibb ($BMY) and Otsuka antipsychotic drug Abilify triggered patients' compulsive gambling. Report

> Sun Pharma and AstraZeneca ($AZN) teamed up on a distribution deal for AZ's diabetes drug Onglyza in Sun's home country of India. Report

> A group of indirect purchasers can move forward with their pay-for-delay claims against GlaxoSmithKline ($GSK) and Teva Pharmaceutical ($TEVA), a New Jersey judge said, citing a previous Third Circuit decision in a similar case. Report

Medical Device News

@FierceMedDev: Dx Digest: Quanterix reels in $46M for international expansion and more. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Medtronic to stop manufacturing some devices in Colorado in pursuit of $850M in promised synergies. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: NICE gives initial thumbs-down to Vertex's CF combo med Orkambi, citing costs. Story | Follow @EmilyWFierce

> Medtronic to stop manufacturing some devices in Colorado in pursuit of $850M in promised synergies. Story

Biotech News

@FierceBiotech: From Chutes & Laddrers: Valeant CEO Mike Pearson out as embattled drugmaker seeks new leadership. More | Follow @FierceBiotech

@JohnCFierce: Bayer looks to protect blockbuster Eylea franchise with $130M Regeneron pact. News | Follow @JohnCFierce

> PTC Therapeutics to cull its ranks after FDA spurns Duchenne drug. Story

> The 'Uber for experiments' group Science Exchange raises $25M. News

> Portola plunges as PhIII blood thinner misses key goal in head-to-head comparison study. Article

> Atlantic Healthcare plots opening of NC office as influence of ex-Salix team grows. More

CRO News

> Global CRO market expected to rocket to $59B by 2020. Story

> NovAliX signs EM-based analysis deal with FEI. More

> Precision for Medicine broadens cancer trial offering with ACT Oncology buy. Report

> Quintiles, Mitsui and investors pay toward a new $866M development fund. Story

> BioPharmaSpec plots Asian expansion with a focus on biosimilars. Article

Pharma Manufacturing News

> Seqirus reviews its manpower needs as it integrates Novartis flu operations. Article

> Vetter's building binge continues with ground-breaking for another Schuetzenstrasse facility. More

> China, in typical fashion, arrests dozens as drug oversight draws attention. Story

> First FDA-approved 3-D manufactured drug hits the market. Item

> Cadila faces new regulatory problems as WHO piles on the pain. More

Pharma Asia News

> Zhejiang Medicine at work with Ambrx on PhI breast cancer candidate. Story

> Ally Bridge keeps cash flowing in $155M private placement in Tesaro. Report

> Taiwan's OBI trial results dispute snares top science research executive. More

> Novartis settlement with U.S. SEC on China bribes one in a string. Story

> China in overdrive on illegal vaccine sales probe. Article

And Finally... Johnson & Johnson ($JNJ) added to its popular collection of "7-Minute" apps with a new version directed at expectant and new mothers. Report